FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products

被引:147
作者
Tamura, Y
Adachi, H
Osuga, J
Ohashi, K
Yahagi, N
Sekiya, M
Okazaki, H
Tomita, S
Iizuka, Y
Shimano, H
Nagai, R
Kimura, S
Tsujimoto, M
Ishibashi, S
机构
[1] Jichi Med Sch, Dept Internal Med, Div Endocrinol & Metab, Kawachi, Tochigi 3290498, Japan
[2] Univ Tokyo, Fac Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan
[3] Univ Tokyo, Fac Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan
[4] Univ Tokyo, Fac Med, Dept Infect Dis, Bunkyo Ku, Tokyo 1138655, Japan
[5] RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan
[6] Univ Tsukuba, Inst Clin Med, Dept Metab, Tsukuba, Ibaraki 3058575, Japan
[7] Univ Tsukuba, Inst Clin Med, Dept Endocrinol, Tsukuba, Ibaraki 3058575, Japan
[8] Univ Tsukuba, Inst Clin Med, Dept Atherosclerosis, Tsukuba, Ibaraki 3058575, Japan
关键词
D O I
10.1074/jbc.M210211200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Advanced glycation end products (AGEs) are nonenzymatically glycosylated proteins, which accumulate in vascular tissues in aging and diabetes. Receptors for AGEs include scavenger receptors, which recognize acetylated low density lipoproteins (Ac-LDL) such as scavenger receptor class AI/AII (SR-A), cell surface glycoprotein CD36, scavenger receptor class B type I (SRBI), and lectin-like oxidized low density lipoprotein receptor-1. The broad ligand repertoire of these receptors as well as the diversity of the receptors for AGEs have prompted us to examine whether AGEs are also recognized by the novel scavenger receptors, which we have recently isolated from a cDNA library prepared from human umbilical vein endothelial cells, such as the scavenger receptor expressed by endothelial cells-I (SREC-I); the fasciclin EGF-like, laminin-type EGF-like, and link domain-containing scavenger receptor-1 (FEEL-1); and its paralogous protein, FEEL-2. At 4 degreesC, I-125-AGE-bovine serum albumin (BSA) exhibited high affinity specific binding to Chinese hamster ovary (CHO) cells overexpressing FEEL-1 (CHO-FEEL-1) and FEEL-2 (CHO-FEEL-2) with K-d of 2.55 and 1.68 mug/ml, respectively, but not to CHO cells expressing SREC (CHO-SREC) and parent CHO cells. At 37 degreesC, I-125-AGE-BSA was taken up and degraded by CHO-FEEL-1 and CHO-FEEL-2 cells but not by CHO-SREC and parent CHO cells. Thus, the ability to bind Ac-LDL is not necessarily a prerequisite to bind AGEs. The I-125-AGE-BSA binding to CHO-FEEL-1 and CHO-FEEL-2 cells was effectively inhibited by Ac-LDL and polyanionic SR-A inhibitors such as fucoidan, polyinosinic acids, and dextran sulfate but not by native LDL, oxidized LDL, or HDL. FEEL-1, which is expressed by the liver and vascular tissues, may recognize AGEs, thereby contributing to the development of diabetic vascular complications and atherosclerosis.
引用
收藏
页码:12613 / 12617
页数:5
相关论文
共 30 条
  • [11] ANTIBACTERIAL ACTIVITY OF LYSOZYME AND LACTOFERRIN IS INHIBITED BY BINDING OF ADVANCED GLYCATION-MODIFIED PROTEINS TO A CONSERVED MOTIF
    LI, YM
    TAN, AX
    VLASSARA, H
    [J]. NATURE MEDICINE, 1995, 1 (10) : 1057 - 1061
  • [12] Advanced glycation end products increase retinal vascular endothelial growth factor expression
    Lu, M
    Kuroki, M
    Amano, S
    Tolentino, M
    Keough, K
    Kim, I
    Bucala, R
    Adamis, AP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (06) : 1219 - 1224
  • [13] Endocytic uptake of advanced glycation end products by mouse liver sinusoidal endothelial cells is mediated by a scavenger receptor distinct from the macrophage scavenger receptor class A
    Matsumoto, K
    Sano, H
    Nagai, R
    Suzuki, H
    Kodama, T
    Yoshida, M
    Ueda, S
    Smedsrod, B
    Horiuchi, S
    [J]. BIOCHEMICAL JOURNAL, 2000, 352 : 233 - 240
  • [14] NAKAMURA Y, 1993, AM J PATHOL, V143, P1649
  • [15] NEEPER M, 1992, J BIOL CHEM, V267, P14998
  • [16] Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients
    Niwa, T
    Katsuzaki, T
    Miyazaki, S
    Miyazaki, T
    Ishizaki, Y
    Hayase, F
    Tatemichi, N
    Takei, Y
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (06) : 1272 - 1280
  • [17] Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products
    Ohgami, N
    Nagai, R
    Miyazaki, A
    Ikemoto, M
    Arai, H
    Horiuchi, S
    Nakayama, H
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (16) : 13348 - 13355
  • [18] CD36, a member of the class B scavenger receptor family, as a receptor for advanced glycation end products
    Ohgami, N
    Nagai, R
    Ikemoto, M
    Arai, H
    Kuniyasu, A
    Horiuchi, S
    Nakayama, H
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (05) : 3195 - 3202
  • [19] Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
    Park', L
    Raman, KG
    Lee, KJ
    Lu, Y
    Ferran, LJ
    Chow, WS
    Stern, D
    Schmidt, AM
    [J]. NATURE MEDICINE, 1998, 4 (09) : 1025 - 1031
  • [20] The LDL receptor is the major pathway for β-VLDL uptake by mouse peritoneal macrophages
    Perrey, S
    Ishibashi, S
    Kitamine, T
    Osuga, J
    Yagyu, H
    Chen, Z
    Shionoiri, F
    Iizuka, Y
    Yahagi, N
    Tamura, Y
    Ohashi, K
    Harada, K
    Gotoda, T
    Yamada, N
    [J]. ATHEROSCLEROSIS, 2001, 154 (01) : 51 - 60